Characterization of the glycated human cerebrospinal fluid proteome

Journal of Proteomics

Volumn 75, Issue 15, 2012, Pages 4766-4782

  Ramírez Boo, María ^a   Priego Capote, Feliciano ^a,b   Hainard, Alexandre ^a   Gluck, Florent ^a   Burkhard, Pierre ^c   Sanchez, Jean Charles ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Advanced glycation end products; Cerebrospinal fluid; Glycation isotopic labeling; Neurodegenerative disorders; Nonenzymatic glycation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BORONIC ACID DERIVATIVE; GLUCOSE; GLYCOSYLATED PROTEIN; PROTEOME; SUPEROXIDE DISMUTASE;

AFFINITY CHROMATOGRAPHY; ARTICLE; CEREBROSPINAL FLUID; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEOMICS;

AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM DISEASES; GLUCOSE; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; MALE; MASS SPECTROMETRY; PROTEOME; PROTEOMICS;

EID: 84864079268     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.01.017     Document Type: Article

References (73)

1. Monnier V.M. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003, 419:1-15.
2. Baynes J.W., Thorpe S.R. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000, 28:1708-1716.
3. Fu M.X., Requena J.R., Jenkins A.J., Lyons T.J., Baynes J.W., Thorpe S.R. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996, 271:9982-9986.
4. Kuhla B., Haase C., Flach K., Luth H.J., Arendt T., Munch G. Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J Biol Chem 2007, 282:6984-6991.
5. Munch G., Mayer S., Michaelis J., Hipkiss A.R., Riederer P., Muller R., et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta 1997, 1360:17-29.
6. Kasper M., Funk R.H. Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch Gerontol Geriatr 2001, 32:233-243.
7. Ling X., Sakashita N., Takeya M., Nagai R., Horiuchi S., Takahashi K. Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest 1998, 78:1591-1606.
8. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223-234.
9. Baynes J.W. The role of AGEs in aging: causation or correlation. Exp Gerontol 2001, 36:1527-1537.
10. Li J.J., Voisin D., Quiquerez A.L., Bouras C. Differential expression of advanced glycosylation end-products in neurons of different species. Brain Res 1994, 641:285-288.
11. Li J.J., Surini M., Catsicas S., Kawashima E., Bouras C. Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol Aging 1995, 16:69-76.
12. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994, 91:4766-4770.
13. Smith M.A., Sayre L.M., Monnier V.M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995, 18:172-176.
14. Castellani R., Smith M.A., Richey P.L., Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996, 737:195-200.
15. Kaufmann E., Boehm B.O., Sussmuth S.D., Kientsch-Engel R., Sperfeld A., Ludolph A.C., et al. The advanced glycation end-product N epsilon-(carboxymethyl)lysine level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurosci Lett 2004, 371:226-229.
16. Chou S.M., Wang H.S., Taniguchi A., Bucala R. Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med 1998, 4:324-332.
17. Bar K.J., Franke S., Wenda B., Muller S., Kientsch-Engel R., Stein G., et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003, 24:333-338.
18. Sasaki N., Takeuchi M., Chowei H., Kikuchi S., Hayashi Y., Nakano N., et al. Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett 2002, 326:117-120.
19. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
20. Schmidt A.M., Hori O., Brett J., Yan S.D., Wautier J.L., Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994, 14:1521-1528.
21. Vlassara H., Li Y.M., Imani F., Wojciechowicz D., Yang Z., Liu F.T., et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1:634-646.
22. Ohgami N., Nagai R., Ikemoto M., Arai H., Miyazaki A., Hakamata H., et al. CD36, serves as a receptor for advanced glycation endproducts (AGE). J Diabetes Complications 2002, 16:56-59.
23. el Khoury J., Thomas C.A., Loike J.D., Hickman S.E., Cao L., Silverstein S.C. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 1994, 269:10197-10200.
24. Berbaum K., Shanmugam K., Stuchbury G., Wiede F., Korner H., Munch G. Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine 2008, 41:198-203.
25. Shuvaev V.V., Laffont I., Serot J.M., Fujii J., Taniguchi N., Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer's disease. Neurobiol Aging 2001, 22:397-402.
26. Ahmed N., Ahmed U., Thornalley P.J., Hager K., Fleischer G., Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005, 92:255-263.
27. Choei H., Sasaki N., Takeuchi M., Yoshida T., Ukai W., Yamagishi S., et al. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 2004, 108:189-193.
28. Sato T., Shimogaito N., Wu X., Kikuchi S., Yamagishi S., Takeuchi M. Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006, 21:197-208.
29. Takeuchi M., Sato T., Takino J., Kobayashi Y., Furuno S., Kikuchi S., et al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 2007, 69:1358-1366.
30. Ledesma M.D., Bonay P., Colaco C., Avila J. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 1994, 269:21614-21619.
31. Yan S.D., Chen X., Schmidt A.M., Brett J., Godman G., Zou Y.S., et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994, 91:7787-7791.
32. Smith M.A., Taneda S., Richey P.L., Miyata S., Yan S.D., Stern D., et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994, 91:5710-5714.
33. Sasaki N., Fukatsu R., Tsuzuki K., Hayashi Y., Yoshida T., Fujii N., et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am J Pathol 1998, 153:1149-1155.
34. Ahmed N., Dobler D., Dean M., Thornalley P.J. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 2005, 280:5724-5732.
35. Abraham E.C., Cherian M., Smith J.B. Site selectivity in the glycation of alpha A- and alpha B-crystallins by glucose. Biochem Biophys Res Commun 1994, 201:1451-1456.
36. Zhao H.R., Smith J.B., Jiang X.Y., Abraham E.C. Sites of glycation of beta B2-crystallin by glucose and fructose. Biochem Biophys Res Commun 1996, 229:128-133.
37. Zhang Y., Cocklin R.R., Bidasee K.R., Wang M. Rapid determination of advanced glycation end products of proteins using MALDI-TOF-MS and PERL script peptide searching algorithm. J Biomol Tech 2003, 14:224-230.
38. Brock J.W., Cotham W.E., Thorpe S.R., Baynes J.W., Ames J.M. Detection and identification of arginine modifications on methylglyoxal-modified ribonuclease by mass spectrometric analysis. J Mass Spectrom 2007, 42:89-100.
39. Dai Z., Wang B., Sun G., Fan X., Anderson V.E., Monnier V.M. Identification of glucose-derived cross-linking sites in ribonuclease A. J Proteome Res 2008, 7:2756-2768.
40. Priego-Capote F., Ramirez-Boo M., Hoogland C., Scherl A., Mueller M., Lisacek F., Sanchez J.C. Human hemolysate glycated proteome. Anal Chem 2011, 83(14):5673-5680.
41. Priego-Capote F., Scherl A., Muller M., Waridel P., Lisacek F., Sanchez J.C. Glycation isotopic labeling with 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol Cell Proteomics 2010, 9:579-592.
42. Scherl A., Tsai Y.S., Shaffer S.A., Goodlett D.R. Increasing information from shotgun proteomic data by accounting for misassigned precursor ion masses. Proteomics 2008, 8:2791-2797.
43. Elias J.E., Gygi S.P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007, 4:207-214.
44. Jeric I., Versluis C., Horvat S., Heck A.J. Tracing glycoprotein structures: electrospray ionization tandem mass spectrometric analysis of sugar-peptide adducts. J Mass Spectrom 2002, 37:803-811.
45. Frolov A., Hoffmann P., Hoffmann R. Fragmentation behavior of glycated peptides derived from D-glucose, D-fructose and D-ribose in tandem mass spectrometry. J Mass Spectrom 2006, 41:1459-1469.
46. Zhang Q., Petyuk V.A., Schepmoes A.A., Orton D.J., Monroe M.E., Yang F., et al. Analysis of non-enzymatically glycated peptides: neutral-loss-triggered MS(3) versus multi-stage activation tandem mass spectrometry. Rapid Commun Mass Spectrom 2008, 22:3027-3034.
47. Ingenbleek Y., Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 1994, 14:495-533.
48. Melegos D.N., Freedman M.S., Diamandis E.P. Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. Prostaglandins 1997, 54:463-474.
49. Tumani H., Nau R., Felgenhauer K. Beta-trace protein in cerebrospinal fluid: a blood-CSF barrier-related evaluation in neurological diseases. Ann Neurol 1998, 44:882-889.
50. Danze P.M., Tarjoman A., Rousseaux J., Fossati P., Dautrevaux M. Evidence for an increased glycation of IgG in diabetic patients. Clin Chim Acta 1987, 166:143-153.
51. Barnaby O.S., Cerny R.L., Clarke W., Hage D.S. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta 2010, 412:277-285.
52. Waybright T., Avellino A.M., Ellenbogen R.G., Hollinger B.J., Veenstra T.D., Morrison R.S. Characterization of the human ventricular cerebrospinal fluid proteome obtained from hydrocephalic patients. J Proteomics 2010, 73:1156-1162.
53. Zougman A., Pilch B., Podtelejnikov A., Kiehntopf M., Schnabel C., Kumar C., et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 2008, 7:386-399.
54. Wenner B.R., Lovell M.A., Lynn B.C. Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS. J Proteome Res 2004, 3:97-103.
55. Zhang J., Goodlett D.R., Peskind E.R., Quinn J.F., Zhou Y., Wang Q., et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 2005, 26:207-227.
56. Gawinecka J., Dieks J., Asif A.R., Carimalo J., Heinemann U., Streich J.H., et al. Codon 129 polymorphism specific cerebrospinal fluid proteome pattern in sporadic Creutzfeldt-Jakob disease and the implication of glycolytic enzymes in prion-induced pathology. J Proteome Res 2010, 9:5646-5657.
57. Khwaja F.W., Reed M.S., Olson J.J., Schmotzer B.J., Gillespie G.Y., Guha A., et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007, 6:559-570.
58. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
59. Steele M., Stuchbury G., Munch G. The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol 2007, 42:28-36.
60. Pamplona R., Naudi A., Gavin R., Pastrana M.A., Sajnani G., Ilieva E.V., et al. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 2008, 45:1159-1166.
61. Hu Y., Malone J.P., Fagan A.M., Townsend R.R., Holtzman D.M. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 2005, 4:2000-2009.
62. Noben J.P., Dumont D., Kwasnikowska N., Verhaert P., Somers V., Hupperts R., et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2006, 5:1647-1657.
63. Fang Q., Strand A., Law W., Faca V.M., Fitzgibbon M.P., Hamel N., et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 2009, 8:451-466.
64. Sanchez J.C., Guillaume E., Lescuyer P., Allard L., Carrette O., Scherl A., et al. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4:2229-2233.
65. Zhang J., Goodlett D.R., Quinn J.F., Peskind E., Kaye J.A., Zhou Y., et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 2005, 7:125-133. discussion 73-80.
66. Pan S., Rush J., Peskind E.R., Galasko D., Chung K., Quinn J., et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 2008, 7:720-730.
67. Serot J.M., Christmann D., Dubost T., Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997, 63:506-508.
68. Pendyala G., Trauger S.A., Kalisiak E., Ellis R.J., Siuzdak G., Fox H.S. Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys. J Proteome Res 2009, 8:2253-2260.
69. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology 2000, 20:8-22.
70. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
71. Lescuyer P., Gandini A., Burkhard P.R., Hochstrasser D.F., Sanchez J.C. Prostaglandin D2 synthase and its post-translational modifications in neurological disorders. Electrophoresis 2005, 26:4563-4570.
72. Pan S., Zhu D., Quinn J.F., Peskind E.R., Montine T.J., Lin B., et al. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 2007, 7:469-473.
73. Castano E.M., Roher A.E., Esh C.L., Kokjohn T.A., Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006, 28:155-163.